openPR Logo
Press release

Spinal Cord Injury Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma

07-30-2025 10:00 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Spinal Cord Injury Market to Show Remarkable Growth Trends from

DelveInsight's "Spinal Cord Injury Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Spinal Cord Injury, historical and forecasted epidemiology as well as the Spinal Cord Injury market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Spinal Cord Injury market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Spinal Cord Injury Market Forecast
https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Spinal Cord Injury Market Report:
• The Spinal Cord Injury market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In June 2025, Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotech company focused on developing innovative allogeneic ("off-the-shelf") cell therapies for severe neurological and ophthalmic disorders, announced the addition of new presenters for the 3rd Annual Spinal Cord Injury Investor Symposium (3rd SCIIS). This year's event will be entirely virtual, featuring interactive and on-demand sessions beginning on June 27, 2025.
• In March 2025, Cellino and Matricelf (TASE: MTLF) announced a partnership aimed at advancing the global biomanufacturing of personalized spinal cord injury therapies. This collaboration integrates Cellino's NebulaTM technology with Matricelf's innovative regenerative medicine approach. By combining Cellino's automated production of induced pluripotent stem cells (iPSCs) with Matricelf's double autologous 3D differentiation process, the partnership seeks to enable scalable and patient-specific regenerative treatments. Cellino's NebulaTM, a proprietary closed-cassette biomanufacturing platform, is specifically designed to generate high-quality iPSCs with exceptional consistency and sterility at a large scale.
• In March 2025, NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) announced the successful completion of a key preclinical study supporting its upcoming Investigational New Drug (IND) application. This study marks a significant step toward the company's first-in-human trials. The results demonstrated that ExoPTEN treatment, across various dosing regimens, promoted motor function recovery and notably enhanced blood flow at the spinal cord injury site-both critical factors for tissue repair and functional improvement.
• In February 2025, Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotech company developing allogeneic cell therapies for severe neurological disorders, announced the launch of its DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical study. This study aims to assess the safety and performance of the Manual Inject Parenchymal Spinal Delivery System (MI PSD System), a new device designed to precisely deliver OPC1, an investigational allogeneic stem cell-based therapy, directly to the spinal cord injury site. OPC1 consists of oligodendrocyte progenitor cells and other related glial cells intended to promote spinal cord repair.
• In February 2025, A pilot clinical trial suggests that spinal cord stimulation (SCS) may help reactivate dormant motor neurons and enhance leg muscle strength in individuals with spinal muscular atrophy (SMA). Researchers from the University of Pittsburgh School of Medicine conducted the study (NCT05430113), utilizing Medtronic's Vectris SureScan device in three SMA patients. After three months of treatment, all participants showed an improvement of at least 20 meters in the six-minute walk test (6MWT), an indicator used to assess muscle endurance and fatigue.
• As per the World Health Organization (WHO) in 2024, there are more than 15 million individuals worldwide living with spinal cord injuries.
• According to Bennett et al. (2022), there are around 17,000 fresh incidents of spinal cord injury (SCI) reported annually in the United States, with an estimated 282,000 individuals living with SCI.
• The projected number of identified cases of Spinal Cord Injury across the 7MM (Seven Major Markets) was roughly 725k cases in 2022, with an anticipated rise anticipated during the forecasted period from 2022 to 2032.
• According to the National Spinal Cord Injury Statistical Center (NSCISC) (2024), the yearly occurrence rate of traumatic spinal cord injury (tSCI) stands at roughly 54 cases per one million individuals in the United States. This equates to approximately 18,000 new tSCI incidents annually.
• The estimated number of diagnosed Spinal Cord Injury cases in the US in 2022 stood at approximately 326k with an anticipated rise projected during the forecasted period.
• Key Spinal Cord Injury Companies: Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma, VA Office of Research and Development/Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc, AbbVie, and others
• Key Spinal Cord Injury Therapies: KP-100IT, NEURO-CELLS, ABT-555 (elezanumab), MT-3921, AST-OPC1, NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, MT-3921, Elezanumab, and others
• The Spinal Cord Injury epidemiology based on gender analyzed that Males are affected more as compared to females, in case of Spinal Cord Injury
• The Spinal Cord Injury market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Spinal Cord Injury pipeline products will significantly revolutionize the Spinal Cord Injury market dynamics.

Spinal Cord Injury Overview
A spinal cord injury (SCI) refers to damage to the spinal cord that results in a loss of function, sensation, or mobility. It can occur due to trauma, such as accidents or falls, or non-traumatic causes like infections or diseases. The severity of an SCI depends on factors such as the location and extent of the injury.

Get a Free sample for the Spinal Cord Injury Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Spinal Cord Injury Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Spinal Cord Injury Epidemiology Segmentation:
The Spinal Cord Injury market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Spinal Cord Injury
• Prevalent Cases of Spinal Cord Injury by severity
• Gender-specific Prevalence of Spinal Cord Injury
• Diagnosed Cases of Episodic and Chronic Spinal Cord Injury

Download the report to understand which factors are driving Spinal Cord Injury epidemiology trends @ Spinal Cord Injury Epidemiology Forecast
https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Spinal Cord Injury Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Spinal Cord Injury market or expected to get launched during the study period. The analysis covers Spinal Cord Injury market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Spinal Cord Injury Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Spinal Cord Injury Therapies and Key Companies
• KP-100IT: Kringle Pharma
• NEURO-CELLS: Neuroplast
• ABT-555 (elezanumab): Abbvie
• MT-3921: Mitsubishi Tanabe Pharma
• AST-OPC1: Lineage Cell Therapeutics
• NVG-291: NervGen Pharma
• Romosozumab: VA Office of Research and Development/Kessler Institute for Rehabilitation
• Umbilical Cord Blood Mononuclear Cell: StemCyte, Inc.
• MT-3921: Mitsubishi Tanabe Pharma America Inc.
• Elezanumab: AbbVie

Discover more about therapies set to grab major Spinal Cord Injury market share @ Spinal Cord Injury Treatment Landscape
https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Spinal Cord Injury Market Strengths
• Both universities and industries are coming up with better approaches aiming towards development of a novel therapy
• Advances in understanding of Spinal Cord Injury pathophysiology over recent years has however led to a surge of clinical trials

Spinal Cord Injury Market Opportunities
• Recent continuous efforts in basic and clinical research are creating new path to regenerative medicine for Spinal Cord Injury
• Absence of an effective therapy targeting symptoms and complications associated with Spinal Cord Injury

Scope of the Spinal Cord Injury Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Spinal Cord Injury Companies: Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma, VA Office of Research and Development/Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc, AbbVie, and others
• Key Spinal Cord Injury Therapies: KP-100IT, NEURO-CELLS, ABT-555 (elezanumab), MT-3921, AST-OPC1, NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, MT-3921, Elezanumab, and others
• Spinal Cord Injury Therapeutic Assessment: Spinal Cord Injury current marketed and Spinal Cord Injury emerging therapies
• Spinal Cord Injury Market Dynamics: Spinal Cord Injury market drivers and Spinal Cord Injury market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Spinal Cord Injury Unmet Needs, KOL's views, Analyst's views, Spinal Cord Injury Market Access and Reimbursement

To know more about Spinal Cord Injury companies working in the treatment market, visit @ Spinal Cord Injury Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Spinal Cord Injury Market Report Introduction
2. Executive Summary for Spinal Cord Injury
3. SWOT analysis of Spinal Cord Injury
4. Spinal Cord Injury Patient Share (%) Overview at a Glance
5. Spinal Cord Injury Market Overview at a Glance
6. Spinal Cord Injury Disease Background and Overview
7. Spinal Cord Injury Epidemiology and Patient Population
8. Country-Specific Patient Population of Spinal Cord Injury
9. Spinal Cord Injury Current Treatment and Medical Practices
10. Spinal Cord Injury Unmet Needs
11. Spinal Cord Injury Emerging Therapies
12. Spinal Cord Injury Market Outlook
13. Country-Wise Spinal Cord Injury Market Analysis (2020-2034)
14. Spinal Cord Injury Market Access and Reimbursement of Therapies
15. Spinal Cord Injury Market Drivers
16. Spinal Cord Injury Market Barriers
17. Spinal Cord Injury Appendix
18. Spinal Cord Injury Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports by DelveInsight

• Scoliosis Market: https://www.delveinsight.com/report-store/scoliosis-market
• Psoriasis Market: https://www.delveinsight.com/report-store/psoriasis-market
• Tendinitis Market: https://www.delveinsight.com/report-store/tendonitis-market
• Vascular Closure Devices Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Hydrocephalus Market: https://www.delveinsight.com/report-store/hydrocephalus-market
• Hemophilia A Market: https://www.delveinsight.com/report-store/hemophilia-a2030-market
• Herpes Simplex Virus Market: https://www.delveinsight.com/report-store/genital-herpes-market
• Peripheral Nerve Injuries Market: https://www.delveinsight.com/infographics/peripheral-nerve-injuries-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Spinal Cord Injury Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma here

News-ID: 4127149 • Views:

More Releases from DelveInsight Business Research

Non-Alcoholic Steatohepatitis Market Set to Grow Substantially Through 2034, DelveInsight Projects | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal Pharma, Inc, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bi
Non-Alcoholic Steatohepatitis Market Set to Grow Substantially Through 2034, Del …
DelveInsight's "Non-Alcoholic Steatohepatitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Non-Alcoholic Steatohepatitis, historical and forecasted epidemiology as well as the Non-Alcoholic Steatohepatitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Non-Alcoholic Steatohepatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Alcoholic Steatohepatitis Market Forecast https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
ESR1 Mutated Metastatic Breast Cancer Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Sanofi, Sun Pharma, Zenopharm, Arvinas, Sermonix Pharma, H3 Biomedicine, Radius Pharma, Menarini Group, Pfizer, G1 Therapeutics
ESR1 Mutated Metastatic Breast Cancer Market Predicted to See Upsurge Through 20 …
DelveInsight's "ESR1 Mutated Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the ESR1 Mutated Metastatic Breast Cancer, historical and forecasted epidemiology as well as the ESR1 Mutated Metastatic Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the ESR1 Mutated Metastatic Breast Cancer market outlook, drug uptake, treatment scenario
Myasthenia Gravis Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Argenx-Halozyme
Myasthenia Gravis Market Growth to Accelerate in Forecast Period (2024-2034), De …
DelveInsight's "Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Myasthenia Gravis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myasthenia Gravis Market Forecast https://www.delveinsight.com/sample-request/myasthenia-gravis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Degenerative Disc Disease Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, Histogen, Boehringer Ingelheim, SpineOvations, Spine B
Degenerative Disc Disease Pipeline 2025: Latest FDA Approvals, Clinical Trials, …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Degenerative Disc Disease pipeline constitutes 15+ key companies continuously working towards developing 15+ Degenerative Disc Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Degenerative Disc Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.

All 5 Releases


More Releases for Cord

Cord Blood Banking Services Market Detailed In New Research Report 2025 | China …
New Report Highlights Key Insights in the Cord Blood Banking Services Market (2025-2032) Cord Blood Banking Services Market is estimated to be valued at USD 38.05 Bn in 2025 and is expected to reach USD 57.59 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032. Coherent Market Insights has published a detailed report titled "Cord Blood Banking Services Market: Industry Trends, Share, Size, Growth, Opportunity,
Cord Blood Banking Services Market Generated Opportunities, Future Scope 2025-20 …
Cord Blood Banking Services Market is estimated to be valued at USD 38.05 Bn in 2025 and is expected to reach USD 57.59 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032. A new study titled Cord Blood Banking Services Market 2025, published by the Coherent Market Insights, offers information on regional and global markets that is expected to increase in value between 2025
Cord Blood Banking Services Market Detailed In New Research Report 2024 | China …
The Latest research report on the Cord Blood Banking Services Market 2024 provides a comprehensive analysis of the current market landscape, with forecasts extending to 2031. This study combines qualitative and quantitative insights to highlight significant market developments, challenges, competitive dynamics, and potential opportunities and trends shaping the Cord Blood Banking Services Market. The report covers market size, recent trends, growth projections, market share, and development status. Additionally, it examines
Cord Blood Bank Market - U.S. Economy Scenario | Cord for Life, National Cord Bl …
The global cord blood banking services market witnessed significant growth over the past decade owing to the rise in awareness related to the benefits of using cord blood stem cells for the treatment of chronic diseases, such as cancer has led to an increase in the government initiative leading to surge in number of cord blood banks, which is anticipated to fuel the growth of the global cord blood banking
Stem Cell Banking Market Can Become Bigger in Few Years? Cord Blood Registry, Vi …
A detailed study on STEM CELL BANKING Market formulated by Brandessence Market Research, puts together a concise analysis of the growth factors impacting the current business scenario across assorted regions. Significant information pertaining to the industry's size, share, application, and statistics are also summed in the report in order to present an ensemble prediction. In addition, this report undertakes an accurate competitive analysis illustrating the status of market majors in
Cord Blood Banking Services Market Analysis on Key Players (Americord Registry L …
The geographical sector of the Global Cord Blood Banking Services Market comprises the leading regions in the market during the forecast tenure. Facts and figures that are given on the region leading this market are some of the features emphasized under this section of the report. The competitive landscape section of the statistical report presents information on major key players in the global market. On the basis of product profile,